Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hyloris Buys Out Maxigesic IV Royalty Rights From Alter Pharma

As Both Companies Sign A €5.75m Renegotiated License Agreement

Executive Summary

Belgian value-added medicines specialist Hyloris Pharmaceuticals has renegotiated its licensing agreement with Alter Pharma group, wrapping up all previous agreements. Under the new agreement, Hyloris will forego all past commitments and all further future royalty obligations to Alter for Maxigesic IV.

You may also be interested in...

Hyloris On Track To Meet 2024 Target During Half-Year Update

Hyloris CEO Stijn Van Rompay said the firm is on track to meet its target of 30 portfolio products by 2024, delivering a confident Q2 half-year update despite some pushback from the US Food and Drug Administration on its Maxigesic IV compound.

Hyloris Takes Maxigesic IV To South Korea And Panama

After expanding the footprint of Maxigesic IV in several European countries, Hyloris has now received regulatory approvals for the non-opioid post-operative pain treatment in South Korea and Panama. The company remains focused on increasing the global footprint of Maxigesic IV in other countries, including the US. 

Milla Follows Sandoz Partnership With Shortage-Hit Sodium Acetate Launch

Milla Pharmaceuticals, part of the Alter Pharma Group, toasted three milestones as it announced approval and launch of its generic version of Pfizer’s sodium acetate 2mEq/ml injectable in the US.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts